, Volume 23, Issue 1, pp 41-43
Date: 08 Mar 2014

Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


As cholinergic mechanisms may be at least partially responsible for hallucinations and delusions in Parkinson’s disease (PD), we conducted an open study in 8 PD patients to assess the efficacy and tolerability of the cholinesterase inhibitor donepezil, 5 mg at bedtime for two months, in the treatment of these complications. Hallucinations and delusions improved significantly in all patients. Donezepil was overall well tolerated, but a deterioration in motor disability was noted in 2 out of 8 patients.

Received: 21 september 2001 / Accepted in revised form: 6 February 2002